Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yueqin Quan"'
Autor:
Kim Margolin, Ludmila Danilova, Maria L Ascierto, Russell C Rockne, Alberto Mendoza Valderrey, Daria M Kessler, Douglas A Hanes, Ethan Dettmann, Kai Rau, Yueqin Quan, Stacey Stern, Daniel F Kelly, Garni Barkhoudarian, Steven E Kolker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/af0d3217472749ba8d69e85e7db44f50
Autor:
Ariana K Waters, Sandeep Burma, Annamarie Allnutt, Natsuko Nomura, Yueqin Quan, Elmar Nurmemmedov, Nozomi Tomimatsu, Ivan Babic, Venkata Mahidhar Yenugonda, Santosh Kesari
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is considered one of the most lethal forms of human cancers, and despite considerable advances in multimodality treatments, it remains an incurable disease with an overall survival of 14 to 16 months after diagnosis. Even in the er
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a91db327be778a2e59b248f76664b38
https://europepmc.org/articles/PMC7650350/
https://europepmc.org/articles/PMC7650350/
Autor:
Santosh Kesari, Surojeet Senugupta, Sivaramakrishna Yadavalli, Yueqin Quan, Natsuko Nomura, Ariana K Waters, Elmar Nurmammadov, Venkata Mahidhar Yenugonda, Diego Marzese, Annamarie Allnutt
Publikováno v:
Cancer Research. 80:P5-05
The absence of hormone and Her2 receptor expression in triple negative breast cancer (TNBC) precludes the use of targeted therapy available for other breast cancer subtypes, and cytotoxic chemotherapy such as paclitaxel and doxorubicin remains the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5249135b2f9c0b51dfba7de9b6d7f80f
https://doi.org/10.1158/1538-7445.sabcs19-p5-05-12
https://doi.org/10.1158/1538-7445.sabcs19-p5-05-12
Autor:
Myung-Shin Sim, Yueqin Quan, Peter Sieling, Hitoe Torisu-Itakura, Delphine J. Lee, Maggie L. DiNome, Mark B. Faries
Publikováno v:
Cancer Research. 75:1315-1315
Introduction: Adoptive cell therapy (ACT) with expanded autologous tumor-infiltrating lymphocytes (TIL) shows promise in melanoma but has not been developed for breast cancer (BC) because BC-TIL have not demonstrated consistent antitumor potency. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e572d7e0a28188f95c20fe0cb5c8eba1
https://doi.org/10.1158/1538-7445.am2015-1315
https://doi.org/10.1158/1538-7445.am2015-1315